Table 2 Prevalence of use of different antihypertensive drug classes in patients treated with one, two or three or more antihypertensive drugs
Whole patient cohort | Patients not taking antidiabetic and/or lipid lowering drugs | |||||
|---|---|---|---|---|---|---|
Patients treated with a single antihypertensive drug | ||||||
| Â | All patients | Male | Female | All patients | Male | Female |
|  | (n = 53; 50.0 ± 10.4 yr) | (n = 16; 49.6 ± 10.9 yr) | (n = 37; 50.2 ± 10.3 yr) | (n = 45; 50.0 ± 10.4 yr) | (n = 11; 48.3 ± 12.2 yr) | (n = 34; 50.2 ± 11.3 yr) |
β-blockers | 15 (28.3) | 1 (6.3) | 14 (37.8)* | 12 (26.7) | ------ | 12 (35.3)* |
ACEIs | 15 (28.3) | 8 (50.0) | 7 (18.9)* | 13 (28.9) | 6 (54.5) | 7 (20.6)* |
ARBs | 13 (24.5) | 5 (31.3) | 8 (21.6) | 12 (26.7) | 4 (36.4) | 8 (23.5) |
CCBs | 7 (13.2) | 2 (12.5) | 5 (13.5) | 6 (13.3) | 1 (9.1) | 5 (14.7) |
Diuretics | 1 (1.9) | ------ | 1 (2.7) | 1 (2.2) | ------ | 1 (2.9) |
α1 adrenergic blockers | 2 (3.8) | ------ | 2 (5.4) | 1 (2.2) | ------ | 1 (2.9) |
Patients treated with two antihypertensive drugs | ||||||
| Â | All patients | Male | Female | All patients | Male | Female |
|  | (n = 47; 53.1 ± 9.5 yr) | (n = 15; 51.7 ± 8.3 yr) | (n = 32; 53.8 ± 10.1 yr) | (n = 38; 52.0 ± 8.7 yr) | (n = 10; 49.9 ± 9.1yr) | (n = 28; 52.8 ± 8.7 yr) |
β-blockers | 12 (25.5) | 3 (20.0) | 10 (31.3) | 10 (26.3) | 1 (10.0) | 9 (32.1) |
ACEIs | 19 (40.4) | 9 (60.0) | 10 (31.3) | 14 (36.8) | 7 (70.0) | 7 (25.0)* |
ARBs | 23 (48.9) | 5 (33.3) | 18 (56.3) | 19 (50.0) | 3 (30.0) | 16 (57.1) |
CCBs | 8 (17.0) | 1 (6.7) | 7 (21.9) | 6 (15.8) | 1 (10.0) | 5 (17.9) |
Diuretics | 30 (63.8) | 11 (73.3) | 19 (59.4) | 26 (68.4) | 8 (80.0) | 18 (64.3) |
α1 adrenergic blockers | 1 (2.1) | ------ | 1 (3.1) | ------- | ------- | ------- |
Patients treated with three or more antihypertensive drugs | ||||||
| Â | All patients | Male | Female | All patients | Male | Female |
|  | (n = 29; 53.6 ± 10.4 yr) | (n = 15; 52.9 ± 9.6 yr) | (n = 14; 54.4 ± 11.5 yr) | (n = 21; 51.3 ± 9.6 yr) | (n = 9; 50.1 ± 9.8 yr) | (n = 12; 52.3 ± 9.8 yr) |
β-blockers | 18 (62.1) | 9 (60.0) | 9 (64.3) | 12 (57.1) | 4 (44.4) | 8 (66.7) |
ACEIs | 6 (20.7) | 2 (13.3) | 4 (28.6) | 6 (28.6) | 2 (22.2) | 4 (33.3) |
ARBs | 19 (65.5) | 10 (66.7) | 9 (64.3) | 14 (66.7) | 6 (66.7) | 8 (61.5) |
CCBs | 10 (34.5) | 9 (60.0) | 1 (7.1)** | 8 (38.1) | 7 (77.8) | 1 (8.3) |
Diuretics | 28 (96.6) | 14 (93.3) | 14 (100) | 21 (100) | 9 (100) | 12 (100) |
α1 adrenergic blockers | 4 (13.8) | 2 (13.3) | 2 (14.3) | 3 (14.3) | 1 (11.1) | 2 (16.7) |